Guardant360 Response

An earlier view of patient response to treatment

Guardant360 ResponseTM is the first blood-only liquid biopsy to view changes in circulating tumor DNA (ctDNA) levels from a simple blood draw to assess early whether a patient is responding to immunotherapy or targeted treatment. The test gives oncologists confidence ahead of scans that treatment is working when ctDNA levels are decreasing, or to allows oncologists to start planning next course of clinical action earlier when ctDNA levels are increasing.

Contact us for any enquiries

Predict treatment response 8 weeks earlier than standard-of-care scans

RECIST (Response Evaluation Criteria in Solid Tumors) is the standard way for oncologists to measure patient treatment response and is based on whether tumors change in size. To use RECIST, there must be at least one tumor that can be measured on X-rays, CT scans, or MRI tests. Studies across cancers and therapies show the Guardant360 Response test can assess a patient’s treatment response 8 weeks earlier than standard-of-care assessing tumor response using RECIST measurements. 1-10

Molecular response predicts progression-free survival

Molecular responders show significantly longer progression-free survival (PFS) rates compared to molecular non-responders across therapies and cancer types in multiple studies. 1-10

  • If ctDNA levels decrease 50% or more (molecular responders), treatment is likely working
  • If ctDNA levels increase (molecular non-responders), treatment is likely not working and the next course of clinical action may be considered by the oncologist
+ Sample requirement

Two 10ml streck tubes.

+ Storage and shipping conditions

Ship same or next day at room temperature. Do not freeze or refrigerate.

Remark: Guardant360 ResponseTM can only be bundle order with Guardant360® CDx or Guardant360 TissueNextTM.

  1. Raja R, Kuziora M, Philip Z. Brohawn PZ, et al. Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. Clin Cancer Res; 2018: 24(24): 6212-6222. DOI: 10.1158/1078-0432.CCR-18-0386.
  2. Aggarwal C,Thompson JC, Chien A, et al. Dynamic monitoring of circulating tumor DNA next-generation gene sequencing as a predictive biomarker of response and progression-free survival after pembrolizumab monotherapy in patients with advanced NSCLC.J Clin Oncol; 2019: 37:15 suppl, 3040-3040. DOI:10.1200/JCO.2019.37.15.
  3. Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med; 2018:24(9):1449-1458. DOI: 10.1038/s41591-018-0101-z.
  4. Shaw AT, Martini JF, Besse B, et al. Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol; 2019: 37:15_suppl, 9019-9019. DOI: 10.1200/JCO.2019.37.15.
  5. Pascual J, Cutts RJ, Kingston B, et al. Assessment of early ctDNA dynamics to predict efficacy of targeted therapies in metastatic breast cancer: Results from plasmaMATCH trial [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res2021;81(4 Suppl):Abstract nr PS5-02.DOI: 10.1158/1538-7445.SABCS20-PS5-02.
  6. Mack PC, Redman MW, Moon J, et al. Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.J Clin Oncol; 2020: 38:15_suppl, 9532-9532. DOI: 10.1200/JCO.2020.38.15.
  7. Maron SB, Chatila WK, Millang BM, et al, Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis. J Clin Oncol; 2020: 38:15_suppl, 4559-4559. DOI: 10.1200/JCO.2020.38.15.
  8. Modi S, Park H, Murthy RK, et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol; 2020: 38(17):1887-1896. DOI: 10.1200/JCO.19.02318.
  9. Zhang Q, Luo J, Wu S, et al. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov; 2020: 10:12, 1842-1853. DOI: 10.1158/2159-8290.CD-20-0047.
  10. Thompson JC, Carpenter EL, Silva BA, et al. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy. JCO Precis; 2021: 5, 510-524. DOI: 10.1200/PO.20.0032.

Download Resources

Guardant360 Patient Brochure Guardant360 Specification Sheet
Are the tests available in Hong Kong?

Guardant Health precision oncology products – Guardant RevealTM, Guardant360® CDx, Guardant360 TissueNextTM are available in Hong Kong through the designated local partner, Codex Genetics.

Where will the tests perform?

The retrieved liquid or tumor biopsy will be performed at Guardant Health laboratory in California, the United States.

As a patient, can I order the tests by myself?

Patients are encouraged to discuss genetic testing options with their healthcare provider. For questions about how to access the tests, please feel free to contact us.

When will the report be ready?

Sample shipment will be arranged on the same or the next day upon sample retrieval. Upon sample received in Guardant Health laboratory in the US, the test report will be ready in around 7 days.

Guardant Health

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum.

Codex Genetics

About Codex Genetics

Codex Genetics enables precision medicine through AI-powered analytics on both genetic and clinical data. We aim to provide holistic, clinically actionable disease management solutions for medical professionals and individuals. We provide services to accelerate diagnostic processes and help disease treatment and disease management.